Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celgene oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), apremilast has met the primary endpoint in PALACE-1 phase III study .
Subscribe to our email newsletter
The double-blind, multi-center, placebo-controlled, parallel-group trial has enrolled 500 patients suffering with psoriatic arthritis, and were randomized 1:1:1 to receive either apremilast, 20 mg BID, 30 mg BID, or identically-appearing placebo for 24 weeks.
The study’s primary endpoint is the proportion of patients in each treatment group who achieved the American College of Rheumatology criteria for 20% improvement (ACR20) compared to baseline at week 16.
Secondary endpoints included other measures of signs and symptoms, physical function and patient-reported outcomes.
Study’s’ overall safety profile was consistent, while compared to the previous phase II program, and tolerability was improved.
The study also met ACR50 and ACR70 endpoints through week 24 in patients from the active treatment arms and also maintained significant improvements.
The PALACE-1 study is ongoing and the study extension remains blinded until all patients complete week 52, according to the company.
Two pivotal randomized, placebo-controlled phase III studies (PALACE 2 and PALACE 3) of apremilast are expected in the third quarter of 2012.
The company is planning to submit combined PALACE study new drug application (NDA) in the first half of 2013, while sNDA and combined MAA in the second half of 2013.